INTERVENTION 1:	Intervention	0
Ixabepilone	Intervention	1
ixabepilone	CHEBI:63605	0-11
Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.	Intervention	2
doxorubicin	CHEBI:28748,BAO:0000639	0-11
cyclophosphamide	CHEBI:4026	16-32
ixabepilone	CHEBI:63605	84-95
Doxorubicin: 60 mg/m2	Intervention	3
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide: 600 mg/m2	Intervention	4
cyclophosphamide	CHEBI:4026	0-16
Ixabepilone (Ixempra): 40 mg/m2	Intervention	5
ixabepilone	CHEBI:63605	0-11
INTERVENTION 2:	Intervention	6
Paclitaxel	Intervention	7
paclitaxel	CHEBI:45863	0-10
Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel given weekly for 12 weeks.	Intervention	8
doxorubicin	CHEBI:28748,BAO:0000639	0-11
cyclophosphamide	CHEBI:4026	16-32
paclitaxel	CHEBI:45863	84-94
Doxorubicin: 60 mg/m2	Intervention	9
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide: 600 mg/m2	Intervention	10
cyclophosphamide	CHEBI:4026	0-16
Paclitaxel (Taxol): 80 mg/m2	Intervention	11
paclitaxel	CHEBI:45863	0-10
Inclusion Criteria:	Eligibility	0
Female patients greater than or equal to18 years of age.	Eligibility	1
female	PATO:0000383	0-6
age	PATO:0000011	52-55
Histologically confirmed invasive unilateral breast cancer (regardless of	Eligibility	2
unilateral	HP:0012833	34-44
breast cancer	DOID:1612	45-58
histology).	Eligibility	3
histology	NCIT:C16681	0-9
Early-stage breast cancer, defined as:	Eligibility	4
breast cancer	DOID:1612	12-25
Node-positive disease: >0.2-mm metastasis in at least one lymph node (pN1mipN2b)OR	Eligibility	5
disease	DOID:4,OGMS:0000031	14-21
lymph	UBERON:0002391	58-63
Node-negative, with primary tumor >1.0 cm (T1c-T3).	Eligibility	6
Definitive loco-regional surgery must have been completed as specified	Eligibility	7
surgery	OAE:0000067	25-32
below:	Eligibility	8
Patients must have undergone either breast conservation surgery	Eligibility	9
breast	UBERON:0000310	36-42
surgery	OAE:0000067	56-63
(i.e., lumpectomy) or total mastectomy.	Eligibility	10
Surgical margins of the resected section must be histologically free of	Eligibility	11
invasive adenocarcinoma and ductal carcinoma in situ.	Eligibility	12
adenocarcinoma	DOID:299	9-23
ductal carcinoma in situ	HP:0030075,DOID:0060074	28-52
Surgical margins involved with lobular carcinoma in situ (LCIS) will not	Eligibility	13
lobular carcinoma in situ	HP:0030076,DOID:3010	31-56
be considered as a positive margin; therefore, such patients will be eligible for this study without additional resection.	Eligibility	14
Patients must have completed axillary lymph node sampling for the pathologic evaluation of axillary lymph nodes as specified below:	Eligibility	15
lymph	UBERON:0002391	38-43
lymph	UBERON:0002391	100-105
Sentinel node biopsy and/or either lymph node sampling procedure or axillary dissection.	Eligibility	16
lymph	UBERON:0002391	35-40
Multicentric and multifocal invasive breast cancer is eligible if loco-regional surgery has been completed as described above.	Eligibility	17
multifocal	HP:0030651	17-27
breast cancer	DOID:1612	37-50
surgery	OAE:0000067	80-87
Patients with synchronous bilateral cancers are eligible only if:	Eligibility	18
bilateral	HP:0012832	26-35
All cancers are of triple-negative phenotype, defined as ER-, PR-, HER2-.	Eligibility	19
Eligibility based on the highest stage grouping.	Eligibility	20
HER2 negative tumors. HER2 negativity must be confirmed by one of the	Eligibility	21
following:	Eligibility	22
FISH-negative (FISH ratio <2.2), or	Eligibility	23
ratio	UO:0000190	20-25
IHC 0-1+, or	Eligibility	24
IHC 2-3+ AND FISH-negative (FISH ratio <2.2).	Eligibility	25
ratio	UO:0000190	33-38
Estrogen receptor negative (<10% staining by IHC for estrogen receptor).	Eligibility	26
estrogen	CHEBI:50114,BAO:0000760	0-8
estrogen	CHEBI:50114,BAO:0000760	53-61
receptor	BAO:0000281	9-17
receptor	BAO:0000281	62-70
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.	Eligibility	27
group	CHEBI:24433	29-34
Patient must be <= 84 days from having completed definitive primary breast surgery (either lumpectomy or mastectomy).	Eligibility	28
patient	HADO:0000008,OAE:0001817	0-7
breast	UBERON:0000310	68-74
surgery	OAE:0000067	75-82
MammoSite brachytherapy radiation is acceptable if it is performed	Eligibility	29
immediately following surgery and prior to chemotherapy. It is recommended that chemotherapy be started no earlier than 2 weeks following the removal of the MammoSite balloon catheter.	Eligibility	30
surgery	OAE:0000067	22-29
Adequate hematologic function, defined by:	Eligibility	31
function	BAO:0003117,BFO:0000034	21-29
Absolute neutrophil count (ANC) >1500/mm3	Eligibility	32
Platelet count >=100,000/mm3	Eligibility	33
platelet count	CMO:0000029	0-14
Hemoglobin >9 g/dL	Eligibility	34
hemoglobin	CHEBI:35143	0-10
Adequate liver function, defined by:	Eligibility	35
liver	UBERON:0002107	9-14
function	BAO:0003117,BFO:0000034	15-23
AST and ALT <=2.5 x the upper limit of normal (ULN)	Eligibility	36
x	LABO:0000148	18-19
Total bilirubin <=1.5 x ULN (unless the patient has grade 1 bilirubin	Eligibility	37
x	LABO:0000148	22-23
patient	HADO:0000008,OAE:0001817	40-47
elevation due to Gilbert's disease or a similar syndrome involving slow	Eligibility	38
disease	DOID:4,OGMS:0000031	27-34
syndrome	DOID:225	48-56
conjugation of bilirubin).	Eligibility	39
Adequate renal function, defined by:	Eligibility	40
function	BAO:0003117,BFO:0000034	15-23
Serum creatinine <=1.5 x ULN	Eligibility	41
creatinine	CHEBI:16737	6-16
x	LABO:0000148	23-24
Complete staging work-up <=12 weeks prior to initiation of study treatment	Eligibility	42
with computed tomography (CT) scans of the chest and abdomen/pelvis (abdomen/pelvis preferred; abdomen accepted), and either a positron emission tomography (PET) scan or a bone scan.	Eligibility	43
tomography	BAO:0002525	14-24
tomography	BAO:0002525	145-155
ct	BAO:0002125	26-28
chest	UBERON:0001443	43-48
abdomen	UBERON:0000916	53-60
abdomen	UBERON:0000916	69-76
abdomen	UBERON:0000916	95-102
positron	CHEBI:30225	127-135
Adequate cardiac function, defined by a left ventricular ejection fraction	Eligibility	44
function	BAO:0003117,BFO:0000034	17-25
left	HP:0012835	40-44
ejection fraction	CMO:0000180	57-74
(LVEF) value of >50% (or normal per institutional guidelines) by MUGA scan or echocardiogram (ECHO).	Eligibility	45
Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of a minor surgery (i.e., sentinel node biopsy, port-acath (placement); at least 3 weeks must have elapsed from the time of a major surgery (i.e., lumpectomy, partial or total mastectomy, axillary lymph node dissection, breast reconstruction procedure).	Eligibility	46
surgery	OAE:0000067	30-37
surgery	OAE:0000067	98-105
surgery	OAE:0000067	219-226
week	UO:0000034	50-54
week	UO:0000034	170-174
time	PATO:0000165	82-86
time	PATO:0000165	203-207
lymph	UBERON:0002391	284-289
breast	UBERON:0000310	307-313
Patients with previous history of invasive cancers (including breast cancer)	Eligibility	47
history	BFO:0000182	23-30
breast cancer	DOID:1612	62-75
are eligible if definitive treatment was completed more than 5 years prior to	Eligibility	48
initiating current study treatment, and there is no evidence of recurrent disease.	Eligibility	49
recurrent	HP:0031796	64-73
disease	DOID:4,OGMS:0000031	74-81
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.	Eligibility	50
urine	UBERON:0001088	62-67
Patient must be accessible for treatment and follow-up.	Eligibility	51
patient	HADO:0000008,OAE:0001817	0-7
Women of childbearing potential must agree to use an acceptable method of birth control to avoid pregnancy for the duration of study treatment, and for 3 months thereafter.	Eligibility	52
duration	PATO:0001309	115-123
All patients must be able to understand the investigational nature of the	Eligibility	53
study and give written informed consent prior to study entry.	Eligibility	54
Exclusion Criteria:	Eligibility	55
Women who are pregnant or breastfeeding.	Eligibility	56
History of previous diagnosis of invasive breast cancer (unless treated >5 years previously with no recurrence). History of previously treated ductal carcinoma in situ (DCIS) is acceptable.	Eligibility	57
history	BFO:0000182	0-7
history	BFO:0000182	113-120
breast cancer	DOID:1612	42-55
ductal carcinoma in situ	HP:0030075,DOID:0060074	143-167
Any evidence or suspicion of metastatic disease other than ipsilateral	Eligibility	58
disease	DOID:4,OGMS:0000031	40-47
axillary lymph nodes.	Eligibility	59
lymph	UBERON:0002391	9-14
Any tumor >=T4 (cutaneous invasion, deep adherence, inflammatory breast cancer).	Eligibility	60
breast cancer	DOID:1612	65-78
Previous anthracycline chemotherapy.	Eligibility	61
anthracycline	CHEBI:48120	9-22
Concurrent use of CYP3A4 inhibitors from 72 hours prior to initiation of	Eligibility	62
study treatment until the end of treatment with ixabepilone.	Eligibility	63
ixabepilone	CHEBI:63605	48-59
Previous treatment for this breast cancer (including neoadjuvant	Eligibility	64
breast cancer	DOID:1612	28-41
chemotherapy).	Eligibility	65
Previous cancer (with the exception of non-melanoma skin cancer or cervical carcinoma in situ) in the past 5 years (including invasive contralateral breast cancer).	Eligibility	66
cancer	DOID:162	9-15
cancer	DOID:162	57-63
cancer	DOID:162	156-162
skin cancer	DOID:4159	52-63
carcinoma	HP:0030731,DOID:305	76-85
breast cancer	DOID:1612	149-162
Peripheral neuropathy of > grade 1 per NCI CTCAE v3.0.	Eligibility	67
peripheral neuropathy	HP:0009830,DOID:870	0-21
Cardiac disease, including: congestive heart failure (CHF) > Class II per	Eligibility	68
disease	DOID:4,OGMS:0000031	8-15
congestive heart failure	HP:0001635,DOID:6000	28-52
New York Heart Association (NYHA) classification; unstable angina (anginal symptoms at rest) or new-onset angina (i.e., began within the last 3 months), or myocardial infarction within the past 6 months; symptomatic CHF, unstable angina pectoris, cardiac arrhythmia, or cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.	Eligibility	69
heart	UBERON:0000948	9-14
myocardial infarction	HP:0001658,DOID:5844	156-177
angina pectoris	HP:0001681	230-245
arrhythmia	HP:0011675	255-265
arrhythmia	HP:0011675	290-300
History of hypersensitivity to CremophorEL (polyoxyethylated castor oil) or	Eligibility	70
history	BFO:0000182	0-7
hypersensitivity	GO:0002524,DOID:1205	11-27
castor oil	CHEBI:140618	61-71
a drug formulated in CremophorEL such as paclitaxel.	Eligibility	71
drug	CHEBI:23888	2-6
paclitaxel	CHEBI:45863	41-51
Use of any investigational agent within 30 days of administration of the first dose of study drug.	Eligibility	72
drug	CHEBI:23888	93-97
Patients may not receive any other investigational or anti-cancer treatments while participating in this study.	Eligibility	73
Concurrent severe, uncontrolled infection or intercurrent illness including,	Eligibility	74
severe	HP:0012828	11-17
but not limited to, ongoing or active infection, or psychiatric illness/social	Eligibility	75
active	PATO:0002354	31-37
situations that would limit compliance with study requirements.	Eligibility	76
Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.	Eligibility	77
condition	PDRO:0000129	7-16
patient	HADO:0000008,OAE:0001817	36-43
Inability to comply with study and/or follow-up procedures.	Eligibility	78
Outcome Measurement:	Results	0
Disease-free Survival	Results	1
The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause.	Results	2
time	PATO:0000165	125-129
disease	DOID:4,OGMS:0000031	36-43
disease	DOID:4,OGMS:0000031	76-83
disease	DOID:4,OGMS:0000031	185-192
death	OAE:0000632	208-213
Time frame: up to 5.25 years (63 months)	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ixabepilone	Results	5
ixabepilone	CHEBI:63605	17-28
Arm/Group Description: Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by ixabepilone every 3 weeks for 4 cycles.	Results	6
doxorubicin	CHEBI:28748,BAO:0000639	23-34
cyclophosphamide	CHEBI:4026	39-55
ixabepilone	CHEBI:63605	107-118
Doxorubicin: 60 mg/m2	Results	7
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide: 600 mg/m2	Results	8
cyclophosphamide	CHEBI:4026	0-16
Ixabepilone (Ixempra): 40 mg/m2	Results	9
ixabepilone	CHEBI:63605	0-11
Overall Number of Participants Analyzed: 306	Results	10
Measure Type: Number	Results	11
Unit of Measure: percentage of participants  3-year DFS: 88.6        (84.3 to 91.8)	Results	12
5-year DFS: 87.1        (82.6 to 90.5)	Results	13
Results 2:	Results	14
Arm/Group Title: Paclitaxel	Results	15
paclitaxel	CHEBI:45863	17-27
Arm/Group Description: Doxorubicin and cyclophosphamide (AC) given every 3 weeks for 4 cycles, followed by paclitaxel given weekly for 12 weeks.	Results	16
doxorubicin	CHEBI:28748,BAO:0000639	23-34
cyclophosphamide	CHEBI:4026	39-55
paclitaxel	CHEBI:45863	107-117
Doxorubicin: 60 mg/m2	Results	17
doxorubicin	CHEBI:28748,BAO:0000639	0-11
Cyclophosphamide: 600 mg/m2	Results	18
cyclophosphamide	CHEBI:4026	0-16
Paclitaxel (Taxol): 80 mg/m2	Results	19
paclitaxel	CHEBI:45863	0-10
Overall Number of Participants Analyzed: 308	Results	20
Measure Type: Number	Results	21
Unit of Measure: percentage of participants  3-year DFS: 88.8        (84.6 to 91.9)	Results	22
5-year DFS: 84.7        (79.7 to 88.6)	Results	23
Adverse Events 1:	Adverse Events	0
Total: 58/305 (19.02%)	Adverse Events	1
FEBRILE NEUTROPENIA * 12/305 (3.93%)	Adverse Events	2
neutropenia	HP:0001875,DOID:1227	8-19
NEUTROPENIA * 4/305 (1.31%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
ANAEMIA * 2/305 (0.66%)	Adverse Events	4
LEUKOPENIA * 1/305 (0.33%)	Adverse Events	5
leukopenia	HP:0001882,DOID:615	0-10
PANCYTOPENIA * 1/305 (0.33%)	Adverse Events	6
pancytopenia	HP:0001876,DOID:12450	0-12
THROMBOCYTOPENIA * 1/305 (0.33%)	Adverse Events	7
thrombocytopenia	HP:0001873,DOID:1588	0-16
DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%)	Adverse Events	8
disseminated intravascular coagulation	HP:0005521,DOID:11247	0-38
ATRIAL FIBRILLATION * 1/305 (0.33%)	Adverse Events	9
atrial fibrillation	HP:0005110,DOID:0060224	0-19
DIASTOLIC DYSFUNCTION * 1/305 (0.33%)	Adverse Events	10
PERICARDIAL EFFUSION * 1/305 (0.33%)	Adverse Events	11
pericardial effusion	HP:0001698,DOID:118	0-20
Adverse Events 2:	Adverse Events	12
Total: 50/304 (16.45%)	Adverse Events	13
FEBRILE NEUTROPENIA * 12/304 (3.95%)	Adverse Events	14
neutropenia	HP:0001875,DOID:1227	8-19
NEUTROPENIA * 1/304 (0.33%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	0-11
ANAEMIA * 0/304 (0.00%)	Adverse Events	16
LEUKOPENIA * 0/304 (0.00%)	Adverse Events	17
leukopenia	HP:0001882,DOID:615	0-10
PANCYTOPENIA * 0/304 (0.00%)	Adverse Events	18
pancytopenia	HP:0001876,DOID:12450	0-12
THROMBOCYTOPENIA * 0/304 (0.00%)	Adverse Events	19
thrombocytopenia	HP:0001873,DOID:1588	0-16
DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%)	Adverse Events	20
disseminated intravascular coagulation	HP:0005521,DOID:11247	0-38
ATRIAL FIBRILLATION * 1/304 (0.33%)	Adverse Events	21
atrial fibrillation	HP:0005110,DOID:0060224	0-19
DIASTOLIC DYSFUNCTION * 0/304 (0.00%)	Adverse Events	22
PERICARDIAL EFFUSION * 0/304 (0.00%)	Adverse Events	23
pericardial effusion	HP:0001698,DOID:118	0-20
